AstraZeneca (AZN): Q2 sales -21% to $6.66B vs. $6.95B consensus. Core EPS -12% to $1.53 vs....

|About: AstraZeneca Group plc (AZN)|By:, SA News Editor
AstraZeneca (AZN): Q2 sales -21% to $6.66B vs. $6.95B consensus. Core EPS -12% to $1.53 vs. $1.39 consensus. Shares -2.5% premarket. (PR .pdf)